Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Specific single nucleotides polymorphisms (SNPs) rs4977756 (CDKN2A/B), rs6010620 (RTEL1), rs498872 (PHLDB1), rs2736100 (TERT), and rs4295627 (CCDC26) have been associated with glioma susceptibility and are potential risk biomarkers.
|
31721021 |
2020 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The Investigating and defining if glial tumors with CDKN2A/B and MTAP homozygous loss may be vulnerable to new forms of therapy, namely those affecting the methionine salvage pathway, was proven to be of importance.
|
30558563 |
2018 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.
|
29105198 |
2018 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although not sufficient on its own, IDH1<sup>R132H</sup> cooperated with PDGFA and loss of Cdkn2a, Atrx, and Pten to promote glioma development in vivo.
|
29719265 |
2018 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The median methylation level of MGMT in glioma samples was 64.65% (IQR, 54.87%-74.37%) compared to 38.30% (IQR, 34.13%-45.45%) in healthy controls, and all revealed significant differences including P16.
|
29100349 |
2017 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The pooled results showed that there was an obvious association of CDKN2A/B rs4977756 polymorphism with risk of glioma in all four comparison models (dominant model/AG + GG vs. AA: OR = 1.36, 95 %CI = 1.20-1.54, p < 0.01; heterozygote comparison/AG vs. AA: OR = 1.31, 95 %CI = 1.12-1.53, p < 0.01; homozygote comparison/GG versus AA: OR = 1.49, 95 %CI = 1.36-1.64, p < 0.01; additive model/G vs. A: OR = 1.23, 95 %CI = 1.18-1.28, p < 0.01, respectively).
|
26577493 |
2016 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that CDKN2A testing may provide further clinical aid in lower-grade glioma substratification beyond IDH mutation and 1p19q codeletion status, particularly in IDH/TP53 mutated astrocytomas.
|
25853694 |
2015 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings show that CDKN2 p16 540 C>G, CDKN2 p16 580 C>T and MDM2 SNP309 T>G variants and their haplotypes may be risk factors for the development of primary brain tumors, especially of glioma.
|
26124340 |
2015 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we analyzed the deletion status of all three exons of p16 and frequency of exon 2 somatic point mutations in glioma from the Indian population and its clinical implications.
|
24065197 |
2014 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) at 7 loci influencing glioma risk: rs2736100 (TERT), rs11979158 and rs2252586 (EGFR), rs4295627 (CCDC26), rs4977756 (CDKN2A/CDKN2B), rs498872 (PHLDB1), and rs6010620 (RTEL1).
|
23161787 |
2013 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The genetic variants associated with the risk of glioma in the EGFR gene have also been associated with specific somatic aberrations, including loss at the CDKN2A/B locus and allele specific loss of EGFR in the tumors.
|
24184969 |
2013 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In analyses including glioma cases with a family history of brain tumours (n = 104) and control subjects free of glioma at baseline, three of seven SNPs were associated with glioma risk: rs2736100 (5p15.33, TERT), rs4977756 (9p21.3, CDKN2A-CDKN2B) and rs6010620 (20q13.33, RTEL1).
|
23115063 |
2013 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Despite the dependency of primary gliomas on continued KRas signaling, a significant percentage of tumors progressed to a KRas-independent state in the absence of Ink4a/Arf expression, demonstrating that these tumor suppressors play a critical role in the suppression of glioma recurrence.
|
22015595 |
2012 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our previous study has shown that inhibitor of differentiation 4 (ID4) dedifferentiates Ink4a/Arf(-/-) mouse astrocytes and human glioma cells to glioma stem-like cells (induced GSCs or iGSCs).
|
21531766 |
2011 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glioma progression is associated with elevated growth factor signaling and loss of function of tumor suppressors Ink4a, Arf and Pten.
|
21754979 |
2011 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Three of the gene variants (rs4295627, a variant of CCDC26; rs4977756, a variant of CDKN2A and CDKN2B; and rs6010620, a variant of RTEL1) were statistically significantly associated with glioma risk in the present population.
|
21920947 |
2011 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The average percentage of methylation in the promoter region of p14ARF gene in brain samples from glioma patients is 39.4%, while 0 from autopsy donors.
|
20714943 |
2011 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association study identifies that CDKN2A was a susceptibility loci for glioma.
|
21843312 |
2011 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Seven independent chromosomal loci have robustly been associated with glioma risk: 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A-CDKN2B), 20q13.33 (rs6010620, RTEL1), and 11q23.3 (rs498872, PHLDB1), and two loci at 7p11.2 (rs11979158 and rs2252586, EGFR).
|
21825990 |
2011 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
|
21057530 |
2011 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Two recent genome-wide association studies reported that single nucleotide polymorphisms (SNPs) in (or near) TERT (5p15), CCDC26 (8q24), CDKN2A/B (9p21), PHLDB1 (11q23), and RTEL1 (20q13) are associated with infiltrating glioma.
|
21356187 |
2011 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Reactivation of p53 by either gene transfer or pharmacologic approaches may compensate for loss of p19Arf or excess mdm2 expression, common events in melanoma and glioma.
|
20569441 |
2010 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings provide no evidence that p16(INK4A)/p14(ARF) and p53 mutations contribute significantly to familial glioma.
|
20455025 |
2010 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association data have identified common genetic variants at 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A-CDKN2B), 11q23.3 (rs498872, PHLDB1), and 20q13.33 (rs6010620, RTEL1) as determinants of glioma risk.
|
20462933 |
2010 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies have recently identified single-nucleotide polymorphisms (SNP) in five loci at 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A/CDKN2B), 20q13.33 (rs6010620, RTEL1), and 11q23.3 (rs498872, PHLDB1) to be associated with glioma risk.
|
20847058 |
2010 |